STAT |
Sanofi and Regeneron encounter more payer resistance over new …
STAT Once again, Sanofi and Regeneron Pharmaceuticals are running into roadblocks trying to win over payers with their new drug for severe eczema. This time a U.K. government watchdog decided the drug would not be cost effective. Sanofi makes double EU filing for cancer and asthma drugs Sanofi responds to draft NICE guidance for its innovative atopic dermatitis drug Dupixent® ? (dupilumab)[i] Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN |
